164 related articles for article (PubMed ID: 26839889)
1. Blood Glucose Fluctuations in Type 2 Diabetes Patients Treated with Multiple Daily Injections.
Li FF; Fu LY; Zhang WL; Su XF; Wu JD; Sun J; Ye L; Ma JH
J Diabetes Res; 2016; 2016():1028945. PubMed ID: 26839889
[TBL] [Abstract][Full Text] [Related]
2. Safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes switching from basal-bolus insulin regimens in the A1chieve study.
Dieuzeide G; Chuang LM; Almaghamsi A; Zilov A; Chen JW; Lavalle-González FJ
Prim Care Diabetes; 2014 Jul; 8(2):111-7. PubMed ID: 23953707
[TBL] [Abstract][Full Text] [Related]
3. Comparison of exenatide with biphasic insulin aspart 30 on glucose variability in type 2 diabetes: study protocol for a randomized controlled trial.
Xu S; Liu X; Ming J; Ji Q
Trials; 2016 Mar; 17():160. PubMed ID: 27009108
[TBL] [Abstract][Full Text] [Related]
4. A comparison of biphasic insulin aspart and insulin glargine administered with oral antidiabetic drugs in type 2 diabetes mellitus--a systematic review and meta-analysis.
Rys P; Wojciechowski P; Siejka S; Małecki P; Hak L; Malecki MT
Int J Clin Pract; 2014 Mar; 68(3):304-13. PubMed ID: 24471814
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the Effects of Continuous Subcutaneous Insulin Infusion and Add-On Therapy with Sitagliptin in Patients with Newly Diagnosed Type 2 Diabetes Mellitus.
Wan H; Zhao D; Shen J; Lu L; Zhang T; Chen Z
J Diabetes Res; 2016; 2016():9849328. PubMed ID: 26798658
[TBL] [Abstract][Full Text] [Related]
6. The study of once- and twice-daily biphasic insulin aspart 30 (BIAsp 30) with sitagliptin, and twice-daily BIAsp 30 without sitagliptin, in patients with type 2 diabetes uncontrolled on sitagliptin and metformin-The Sit2Mix trial.
Linjawi S; Sothiratnam R; Sari R; Andersen H; Hiort LC; Rao P
Prim Care Diabetes; 2015 Oct; 9(5):370-6. PubMed ID: 25488587
[TBL] [Abstract][Full Text] [Related]
7. Criteria influencing the choice of starting insulin regimen in patients with type 2 diabetes in routine clinical practice: baseline data from the Algerian cohort of the A₁chieve study.
Malek R; Arbouche Z; Bachaoui M; Zinai S; Dahaoui A; Senoussaoui S; Salah-Mansour A
Diabetes Res Clin Pract; 2013 Aug; 101 Suppl 1():S45-9. PubMed ID: 23958572
[TBL] [Abstract][Full Text] [Related]
8. Treatment of prednisolone-induced hyperglycaemia in hospitalized patients: Insights from a randomized, controlled study.
Radhakutty A; Stranks JL; Mangelsdorf BL; Drake SM; Roberts GW; Zimmermann AT; Stranks SN; Thompson CH; Burt MG
Diabetes Obes Metab; 2017 Apr; 19(4):571-578. PubMed ID: 27995731
[TBL] [Abstract][Full Text] [Related]
9. Biphasic insulin aspart 30 improved glycemic control in Chinese patients with type 2 diabetes poorly controlled on oral glucose-lowering drugs: a subgroup analysis of the A₁chieve study.
Chen L; Xing X; Lei M; Liu J; Shi Y; Li P; Qin G; Li C; Li Y; Wang Q; Gao T; Hu L; Wang Y; Yang W
Chin Med J (Engl); 2014; 127(2):208-12. PubMed ID: 24438605
[TBL] [Abstract][Full Text] [Related]
10. Phase III Study on Efficacy and Safety of Triple Combination (Exenatide/Metformin/Biphasic Insulin Aspart) Therapy for Type 2 Diabetes Mellitus.
Su K; Lv C; Ji Z; Wang Y; Wang H; Bai Y; Liu Y
Am J Ther; 2018; 25(6):e609-e616. PubMed ID: 26844723
[TBL] [Abstract][Full Text] [Related]
11. Safety and effectiveness of biphasic insulin aspart 30 (Biasp 30) in people with type 2 diabetes mellitus in the pakistani population: results from the A1chieve study.
Hassan MI; Aamir AH; Miyan Z; Siddiqui LA; Qureshi MS; Shaikh MZ
J Pak Med Assoc; 2012 Sep; 62(9):929-36. PubMed ID: 23139978
[TBL] [Abstract][Full Text] [Related]
12. Similar glucose control with basal-bolus regimen of insulin detemir plus insulin aspart and thrice-daily biphasic insulin aspart 30 in insulin-naive patients with type 2 diabetes: Results of a 50-week randomized clinical trial of stepwise insulin intensification.
Malek R; Ajili F; Assaad-Khalil SH; Shinde A; Chen JW; Van den Berg E
Diabetes Metab; 2015 Jun; 41(3):223-30. PubMed ID: 25483023
[TBL] [Abstract][Full Text] [Related]
13. Starting or switching to biphasic insulin aspart 30 (BIAsp 30) in type 2 diabetes: a multicenter, observational, primary care study conducted in Finland.
Mäkelä JK; Schmüser C; Askonen K; Saukkonen T
Diabetes Res Clin Pract; 2012 Jan; 95(1):10-8. PubMed ID: 22078072
[TBL] [Abstract][Full Text] [Related]
14. Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII.
Hirsch IB; Bode BW; Garg S; Lane WS; Sussman A; Hu P; Santiago OM; Kolaczynski JW;
Diabetes Care; 2005 Mar; 28(3):533-8. PubMed ID: 15735183
[TBL] [Abstract][Full Text] [Related]
15. Predictors of early discontinuation of basal insulin therapy in type 2 diabetes in primary care.
Kostev K; Dippel FW; Rathmann W
Prim Care Diabetes; 2016 Apr; 10(2):142-7. PubMed ID: 26324105
[TBL] [Abstract][Full Text] [Related]
16. Multicentre randomized controlled trial with sensor-augmented pump vs multiple daily injections in hospitalized patients with type 2 diabetes in China: Time to reach target glucose.
Gu W; Liu Y; Chen Y; Deng W; Ran X; Chen L; Zhu D; Yang J; Shin J; Lee SW; Cordero TL; Mu Y
Diabetes Metab; 2017 Sep; 43(4):359-363. PubMed ID: 28236571
[TBL] [Abstract][Full Text] [Related]
17. Continuous Glucose Monitoring in Newly Diagnosed Type 2 Diabetes Patients Reveals a Potential Risk of Hypoglycemia in Older Men.
Li FF; Liu BL; Zhu HH; Li T; Zhang WL; Su XF; Wu JD; Wang XQ; Xu N; Yu WN; Yuan Q; Qi GC; Ye L; Lee KO; Ma JH
J Diabetes Res; 2017; 2017():2740372. PubMed ID: 28271075
[No Abstract] [Full Text] [Related]
18. Noninferiority effects on glycemic control and β-cell function improvement in newly diagnosed type 2 diabetes patients: basal insulin monotherapy versus continuous subcutaneous insulin infusion treatment.
Zeng L; Lu H; Deng H; Mu P; Li X; Wang M
Diabetes Technol Ther; 2012 Jan; 14(1):35-42. PubMed ID: 21877913
[TBL] [Abstract][Full Text] [Related]
19. Comparison of continuous subcutaneous insulin infusion and multiple daily insulin injections in Chinese patients with type 2 diabetes mellitus.
Yang H; Heng X; Liang C; Liu X; Du W; Li S; Wang Y; Dong Q; Li W; Pan Z; Gong Q; Gao G
J Int Med Res; 2014 Aug; 42(4):1002-10. PubMed ID: 24965335
[TBL] [Abstract][Full Text] [Related]
20. In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine.
Bruttomesso D; Crazzolara D; Maran A; Costa S; Dal Pos M; Girelli A; Lepore G; Aragona M; Iori E; Valentini U; Del Prato S; Tiengo A; Buhr A; Trevisan R; Baritussio A
Diabet Med; 2008 Mar; 25(3):326-32. PubMed ID: 18307459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
